STAT Plus: STAT’s guide to the most important, beneficial drugs approved in the past decade
The new year will end in a zero, making this a perfect opportunity to look…
Category: Pharmaceuticals
LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer
Dateline City: KENILWORTH, N.J. LYNPARZA Reduced the Risk of Disease Progression or Death by 47%…
Opinion: To make advanced therapies, we need to industrialize personalization
What’s the best way to measure the real rate of progress in personalized cell therapies,…
STAT Plus: Prosecutors seek a 15-year jail sentence for former Insys CEO for his role in the opioid crisis
For his role in fomenting the opioid crisis, federal officials want to sentence Insys Therapeutics…
Merck Announces FDA Approval for ERVEBO® (Ebola Zaire Vaccine, Live)
Dateline City: KENILWORTH, N.J. Action Represents Another Milestone for the Global Partnership Against Ebola KENILWORTH,…
Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan for Three New First-Line Indications Across Advanced Renal Cell Carcinoma (RCC) and Recurrent or Distant Metastatic Head and Neck Cancer
Dateline City: KENILWORTH, N.J. KEYTRUDA Now Approved for Six Cancer Types Plus Microsatellite Instability-High (MSI-H)…
Opinion: Aducanumab isn’t the simple solution to the complicated Alzheimer’s crisis
This year’s Clinical Trials on Alzheimer’s Disease meeting began in mid-December with a bang and…
Listen: The decade in breakthrough drugs, the year in bad CEOing, and the viruses that cure disease
Which drug defined the decade? Who’s the worst CEO in biopharma? And how does gene…
Opinion: Manufacturing: the next breakthrough in gene therapy
I never thought I’d see the day when words like “process,” “scale,” and “automation” would…
FDA Oncologic Drugs Advisory Committee (ODAC) Recommends KEYTRUDA® (pembrolizumab) for the Treatment of Certain Patients with High-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC)
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States…
Merck Animal Health Completes Acquisition of Vaki to Further Broaden Its Leadership Position in Aquaculture to Advance Fish Health and Welfare
Dateline City: MADISON, N.J. Strategic Transaction Benefits and Improves Aquaculture Health and Performance MADISON, N.J.–(BUSINESS…
LYNPARZA® (olaparib) Recommended by FDA Advisory Committee for First-Line Maintenance Therapy in Germline BRCA-Mutated Metastatic Pancreatic Cancer That Has Not Progressed on Platinum-Based Chemotherapy
Dateline City: KENILWORTH, N.J. Oncologic Drugs Advisory Committee Voted That LYNPARZA Demonstrated a Favorable Benefit-Risk…
.jpg)
Merck Begins Tender Offer to Acquire ArQule
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Purdue, maker of OxyContin, quietly splits ways with PhRMA as it pulls back from lobbying
WASHINGTON — Purdue Pharma, the embattled opioid maker, has quietly split ways with PhRMA, the…
Merck Receives Positive EU CHMP Opinion for RECARBRIO™ (imipenem, cilastatin, and relebactam) for the Treatment of Infections Due to Aerobic Gram-Negative Organisms in Adults with Limited Treatment Options
Dateline City: KENILWORTH, N.J. Merck (NYSE:MRK), known as MSD outside the United States and Canada,…
Data from Exploratory Analysis Show Merck’s KEYTRUDA® (pembrolizumab) Improved Overall Survival as Monotherapy for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer Regardless of KRAS Mutational Status
Dateline City: KENILWORTH, N.J. New Findings from Phase 3 KEYNOTE-042 Study Were Presented Today at…
‘Dump it down the drain’: How contaminants from prescription-drug factories pollute waterways
A cacophony of machines, some as big as a dump truck, mix pharmaceutical ingredients, press…
Opinion: Do large pharma companies provide drug development innovation? Our analysis says no
Large pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription…
Sanofi says Dupixent could be a $10 billion drug, aims to sell Cialis and Tamiflu over the counter
The new CEO of Sanofi, the French drug giant, believes that its drug Dupixent, for…
Opinion: H.R. 3 is the wrong path to lower drug costs
Americans want health care to be less expensive. We also want our health care to…
Merck to Acquire ArQule, Advancing Leadership in Oncology
Dateline City: KENILWORTH, N.J. & BURLINGTON, Mass. Acquisition Further Diversifies Merck’s Oncology Pipeline with Expansion…
Opinion: Aducanumab: the beginning of the end of Alzheimer’s disease?
In histories written about Alzheimer’s disease, 2019 will turn up as a landmark year, one…
Opinion: Creating a Facebook for cell communication can help treat disease
Everyone, it seems, uses Facebook and LinkedIn these days. Social networking sites make it incredibly…
LYNPARZA® (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer
Dateline City: KENILWORTH, N.J. AstraZeneca and Merck’s LYNPARZA Reduced the Risk of Disease Progression or…
Opinion: Protect patient access to drug infusions administered in physician offices
As gastroenterologists, we treat patients in Portland, Ore., and Des Moines, Iowa, with challenging disorders…
STAT Plus: Congress is hoping for another major medical research bill. But pharma’s not nearly as excited as before
WASHINGTON — The bipartisan duo behind a 2016 law that poured billions into medical research…
Merck to Present at the Evercore ISI HealthCONx Conference 2019
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Certain Patients with High-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC)
Dateline City: KENILWORTH, N.J. Application Based on Results from Phase 2 KEYNOTE-057 Trial, to be…
STAT Plus: Biogen will offer discounts to a health plan if patients say its multiple sclerosis drugs don’t work
In a twist on value-based contracting, a drug maker has agreed to offer a larger…
STAT Plus: Pharmalittle: Feds probe drug makers for flooding communities with opioids; States proceeding with importation
And so, another working week will soon come to an end, but earlier than usual,…
How difficult is a $1 billion health-tech fraud? A new indictment makes it sound easy
Building a health-technology startup on nothing but hot air may be easier than you’d think…
Opinion: In pricing our gene therapy, Bluebird weighed value, shared risk, and a lifetime cap
It is hard to not get emotional when you witness the unfair reality of terrible…
Merck’s KEYTRUDA® (pembrolizumab) Now Approved in China for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy
Dateline City: KENILWORTH, N.J. Third Approval for KEYTRUDA in First-Line NSCLC in China in Less…
Opinion: Barring cisgender women from the Descovy trials was a bad call
Of the estimated 38 million people living with HIV around the world, more than half…
With $9.7 billion acquisition, Novartis bets that heart drugs are coming back
Novartis’ $9.7 billion acquisition of The Medicines Company, which the companies announced Sunday after days…
Listen: Warren’s awkward home front, the ethics of treating dwarfism, and the sound of STAT Summit
Can Sen. Elizabeth Warren ever go home again? Is it ethical to make little people…
European Commission Approves Two New Regimens of Merck’s KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Dateline City: KENILWORTH, N.J. KEYTRUDA is the First Anti-PD-1 Therapy Approved in Europe for the…
OxyContin maker thrives in China with abandoned U.S. tactics
SHANGHAI — OxyContin is a dying business in the United States. Purdue Pharma, owned by…
Opinion: Some bipartisan support for biosimilars is good. More would be better
In today’s hyperpartisan and gridlocked political climate, we should seize any opportunity for bipartisan agreement…
Opinion: Letting academic medical centers make CAR-T drugs would save billions
Draw blood from someone with cancer. Engineer their blood cells to seek and destroy cancer….
How Purdue planted its ‘anti-story’ and delayed the reckoning for its role in the opioid epidemic
This story is a collaboration between STAT and ProPublica. In 2004, Purdue Pharma was facing…
Merck Announces First-Quarter 2020 Dividend
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…